Examkin

Soru

Zorluk: ZorInfectious Diseases

Match the following patients presenting with malaria exposure or active infection to their most appropriate pharmacological management.

  • A 35-year-old woman returns from West Africa with cyclical fever and chills. Blood smears demonstrate Plasmodium falciparum without signs of severe disease. She acquired the infection in a region with known chloroquine resistance.Oral artemether-lumefantrine or atovaquone-proguanil
  • A 28-year-old man experiences recurrent cyclical fevers 6 months after returning from India. Blood smears reveal Plasmodium vivax. Quantitative testing confirms his glucose-6-phosphate dehydrogenase (G6PD) levels are within normal limits.Oral chloroquine followed by a 14-day course of primaquine
  • A 42-year-old man presents with high fever, confusion, and oliguria following a trip to sub-Saharan Africa. Blood smears show Plasmodium falciparum with 8% parasitemia.Intravenous artesunate followed by a complete course of oral artemisinin-based combination therapy
  • A 30-year-old pregnant woman in her first trimester is planning to travel to a chloroquine-resistant malaria endemic region and requests appropriate chemoprophylaxis.Initiation of mefloquine chemoprophylaxis

Cevap

The scenarios match uncomplicated P. falciparum to oral artemether-lumefantrine, P. vivax to chloroquine plus primaquine, severe P. falciparum to IV artesunate, and pregnancy prophylaxis to mefloquine.
Appropriate malaria management requires identifying the infecting species (to determine the need for hypnozoite eradication), assessing clinical severity (to determine the need for intravenous versus oral therapy), understanding regional resistance patterns (to avoid chloroquine in resistant areas), and evaluating patient-specific factors (such as pregnancy or G6PD deficiency).

Adım Adım Çözüm

1
Analyze the clinical scenario to determine the species of Plasmodium and the severity of the infection.
Identified uncomplicated P. falciparum, P. vivax with normal G6PD, severe P. falciparum, and a pregnant traveler needing prophylaxis.
The choice of antimalarial agent depends heavily on the infecting species, resistance patterns, disease severity, and patient-specific contraindications.
2
Match the uncomplicated P. falciparum scenario with its appropriate treatment.
Paired with oral artemether-lumefantrine or atovaquone-proguanil.
Chloroquine resistance is widespread; therefore, artemisinin-based combination therapies (ACTs) or atovaquone-proguanil are the standard of care for uncomplicated P. falciparum.
3
Match the P. vivax scenario with its appropriate treatment.
Paired with oral chloroquine followed by primaquine.
P. vivax forms dormant hypnozoites in the liver. Primaquine is required for radical cure to prevent relapse, but it can only be used after confirming normal G6PD levels to avoid severe hemolysis.
4
Match the severe P. falciparum scenario with its appropriate treatment.
Paired with intravenous artesunate followed by oral ACT.
Features of severe malaria (e.g., altered mental status, oliguria, >5% parasitemia) necessitate rapid parasitemia reduction with IV artesunate, as oral absorption may be compromised.
5
Match the pregnant traveler scenario with the appropriate chemoprophylaxis.
Paired with mefloquine.
Mefloquine is the only safe and effective chemoprophylaxis for pregnant women traveling to chloroquine-resistant areas, especially during the first trimester.

Anahtar Kavram

Pharmacological management of malaria based on species, severity, resistance patterns, and patient-specific contraindications.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru